InSysBio, one of the world's pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with BeOne Medicines, a global oncology company.
Mechanistic PK/RO modeling will be leveraged to support the selection of the optimal recommended phase 2 dose by predicting the dynamics of the various complexes formed when the BGB-B2033 binds to its targets. BGB-B2033, a GPC3 x 4-1BB bispecific antibody, is currently in early clinical development by BeOne Medicines.
"This project represents a valuable opportunity to apply our cutting-edge modeling approach since determining the optimal dose for therapies expected to exhibit a bell-shaped dose-response relationship poses a significant challenge," said Oleg Demin Jr, Scientific Director, InSysBio. "InSysBio's QSP modeling expertise can help to address this issue. Namely, we have developed generic mechanistic PK/RO model for multispecific antibodies that accelerates project timelines and improves efficiency. Moreover, FDA's Project Optimus encourages the application of mechanistic modeling approaches such as QSP to guide the selection of optimal dose in oncology."
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio's cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | November 2020 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
| ||||||
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
|
9
|
10
1.
10 Nov 2020 16:33
InSysBio to release Demo Version of Immune Response Template
[Moscow – 10.11.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, presents the new access mode to Immune Response Template (IRT) version 3. Now any modeler can experience or get acquainted with IRT via Demo access without the necessity to purchase the license.
|
11
|
12
1.
12 Nov 2020 16:36
InSysBio to release CYTOCON DB Open version
CYTOCON DB Open is designed for free public use
[Moscow – 12.11.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, has extended the variety of options to experience its CYTOCON DB with a new way. In general, the database allows to investigate the concentration of multiple species measured in different tissues of patients. Now InSysBio presents its public version entitled “CYTOCON DB Open”.
|
13
|
14
|
15
|
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
|
23
|
24
|
25
|
26
|
27
1.
27 Nov 2020 12:45
InSysBio to run Heta video tutorial on YouTube
InSysBio has recently launched weekly series on YouTube about the Heta language.
Heta is a modeling language for quantitative systems pharmacology and systems biology. Now InSysBio presents the tutorial consisting of short lessons that familiarize with Heta, describe its features and show examples.
|
28
|
29
|
|
30
| ||||||
Thank you for your message! We will get back to you shortly.
